Does the media refer more to LFCR or SLDB?

In the previous week, Solid Biosciences had 1 more articles in the media than Lifecore Biomedical. MarketBeat recorded 3 mentions for Solid Biosciences and 2 mentions for Lifecore Biomedical. Lifecore Biomedical's average media sentiment score of 1.89 beat Solid Biosciences' score of 0.94 indicating that Lifecore Biomedical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lifecore Biomedical 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Solid Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor LFCR or ESPR?

In the previous week, Esperion Therapeutics had 1 more articles in the media than Lifecore Biomedical. MarketBeat recorded 3 mentions for Esperion Therapeutics and 2 mentions for Lifecore Biomedical. Lifecore Biomedical's average media sentiment score of 1.89 beat Esperion Therapeutics' score of 1.42 indicating that Lifecore Biomedical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lifecore Biomedical 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Esperion Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor LFCR or EVMN?

In the previous week, Evommune had 11 more articles in the media than Lifecore Biomedical. MarketBeat recorded 13 mentions for Evommune and 2 mentions for Lifecore Biomedical. Lifecore Biomedical's average media sentiment score of 1.89 beat Evommune's score of -0.53 indicating that Lifecore Biomedical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lifecore Biomedical 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Evommune 1 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Negative

Which has higher valuation & earnings, LFCR or VOR?

Vor Biopharma has lower revenue, but higher earnings than Lifecore Biomedical. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lifecore Biomedical $128.87M 1.53 -$35.26M -$0.94 N/A Vor Biopharma N/A N/A N/A N/A N/A

Does the media favor LFCR or VOR?

In the previous week, Vor Biopharma had 1 more articles in the media than Lifecore Biomedical. MarketBeat recorded 3 mentions for Vor Biopharma and 2 mentions for Lifecore Biomedical. Lifecore Biomedical's average media sentiment score of 1.89 beat Vor Biopharma's score of 0.94 indicating that Lifecore Biomedical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lifecore Biomedical 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Vor Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Lifecore Biomedical (LFCR) Competitors

$5.25 +0.29 (+5.85%)

Closing price 06/30/2026 04:00 PM Eastern

Extended Trading

$5.25 0.00 (0.00%)

As of 06/30/2026 04:51 PM Eastern

Compare

LFCR vs. ANNX, SLDB, ESPR, EVMN, and VOR

Should you buy Lifecore Biomedical stock or one of its competitors? MarketBeat compares Lifecore Biomedical with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Lifecore Biomedical include Annexon (ANNX), Solid Biosciences (SLDB), Esperion Therapeutics (ESPR), Evommune (EVMN), and Vor Biopharma (VOR). These companies are all part of the "pharmaceutical products" industry.

How does Lifecore Biomedical compare to Annexon?

Lifecore Biomedical (NASDAQ:LFCR) and Annexon (NASDAQ:ANNX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, analyst recommendations, profitability and dividends.

Lifecore Biomedical has higher revenue and earnings than Annexon. Lifecore Biomedical is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lifecore Biomedical	$128.87M	1.53	-$35.26M	-$0.94	N/A
Annexon	N/A	N/A	-$206.69M	-$1.22	N/A

83.4% of Lifecore Biomedical shares are held by institutional investors. 32.7% of Lifecore Biomedical shares are held by insiders. Comparatively, 10.3% of Annexon shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Lifecore Biomedical presently has a consensus target price of $6.50, suggesting a potential upside of 23.81%. Annexon has a consensus target price of $16.00, suggesting a potential upside of 180.21%. Given Annexon's stronger consensus rating and higher probable upside, analysts clearly believe Annexon is more favorable than Lifecore Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lifecore Biomedical	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Annexon	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

In the previous week, Lifecore Biomedical had 1 more articles in the media than Annexon. MarketBeat recorded 2 mentions for Lifecore Biomedical and 1 mentions for Annexon. Lifecore Biomedical's average media sentiment score of 1.89 beat Annexon's score of 1.87 indicating that Lifecore Biomedical is being referred to more favorably in the media.

Company	Overall Sentiment
Lifecore Biomedical	Very Positive
Annexon	Very Positive

Annexon has a net margin of 0.00% compared to Lifecore Biomedical's net margin of -25.43%. Annexon's return on equity of -101.19% beat Lifecore Biomedical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lifecore Biomedical	-25.43%	-1,643.15%	-14.40%
Annexon	N/A	-101.19%	-75.99%

Lifecore Biomedical has a beta of 1.06, indicating that its share price is 6% more volatile than the broader market. Comparatively, Annexon has a beta of 1.18, indicating that its share price is 18% more volatile than the broader market.

Summary

Lifecore Biomedical beats Annexon on 8 of the 15 factors compared between the two stocks.

How does Lifecore Biomedical compare to Solid Biosciences?

Lifecore Biomedical (NASDAQ:LFCR) and Solid Biosciences (NASDAQ:SLDB) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, dividends, valuation and earnings.

Lifecore Biomedical has higher revenue and earnings than Solid Biosciences. Lifecore Biomedical is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lifecore Biomedical	$128.87M	1.53	-$35.26M	-$0.94	N/A
Solid Biosciences	N/A	N/A	-$174.32M	-$1.95	N/A

Lifecore Biomedical currently has a consensus price target of $6.50, indicating a potential upside of 23.81%. Solid Biosciences has a consensus price target of $17.00, indicating a potential upside of 70.17%. Given Solid Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Solid Biosciences is more favorable than Lifecore Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lifecore Biomedical	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92

In the previous week, Solid Biosciences had 1 more articles in the media than Lifecore Biomedical. MarketBeat recorded 3 mentions for Solid Biosciences and 2 mentions for Lifecore Biomedical. Lifecore Biomedical's average media sentiment score of 1.89 beat Solid Biosciences' score of 0.94 indicating that Lifecore Biomedical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lifecore Biomedical	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Solid Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

83.4% of Lifecore Biomedical shares are held by institutional investors. Comparatively, 81.5% of Solid Biosciences shares are held by institutional investors. 32.7% of Lifecore Biomedical shares are held by company insiders. Comparatively, 2.7% of Solid Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Solid Biosciences has a net margin of 0.00% compared to Lifecore Biomedical's net margin of -25.43%. Solid Biosciences' return on equity of -73.42% beat Lifecore Biomedical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lifecore Biomedical	-25.43%	-1,643.15%	-14.40%
Solid Biosciences	N/A	-73.42%	-61.13%

Lifecore Biomedical has a beta of 1.06, indicating that its stock price is 6% more volatile than the broader market. Comparatively, Solid Biosciences has a beta of 2.43, indicating that its stock price is 143% more volatile than the broader market.

Summary

Solid Biosciences beats Lifecore Biomedical on 9 of the 16 factors compared between the two stocks.

How does Lifecore Biomedical compare to Esperion Therapeutics?

Lifecore Biomedical (NASDAQ:LFCR) and Esperion Therapeutics (NASDAQ:ESPR) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, media sentiment, profitability, dividends, analyst recommendations and valuation.

Lifecore Biomedical has a beta of 1.06, meaning that its share price is 6% more volatile than the broader market. Comparatively, Esperion Therapeutics has a beta of 1.07, meaning that its share price is 7% more volatile than the broader market.

Esperion Therapeutics has higher revenue and earnings than Lifecore Biomedical. Esperion Therapeutics is trading at a lower price-to-earnings ratio than Lifecore Biomedical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lifecore Biomedical	$128.87M	1.53	-$35.26M	-$0.94	N/A
Esperion Therapeutics	$403.14M	2.02	-$22.68M	-$0.06	N/A

Esperion Therapeutics has a net margin of 0.12% compared to Lifecore Biomedical's net margin of -25.43%. Esperion Therapeutics' return on equity of -0.14% beat Lifecore Biomedical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lifecore Biomedical	-25.43%	-1,643.15%	-14.40%
Esperion Therapeutics	0.12%	-0.14%	0.12%

Lifecore Biomedical presently has a consensus target price of $6.50, indicating a potential upside of 23.81%. Esperion Therapeutics has a consensus target price of $5.54, indicating a potential upside of 75.32%. Given Esperion Therapeutics' higher possible upside, analysts plainly believe Esperion Therapeutics is more favorable than Lifecore Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lifecore Biomedical	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Esperion Therapeutics	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Esperion Therapeutics had 1 more articles in the media than Lifecore Biomedical. MarketBeat recorded 3 mentions for Esperion Therapeutics and 2 mentions for Lifecore Biomedical. Lifecore Biomedical's average media sentiment score of 1.89 beat Esperion Therapeutics' score of 1.42 indicating that Lifecore Biomedical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lifecore Biomedical	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Esperion Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

83.4% of Lifecore Biomedical shares are owned by institutional investors. Comparatively, 47.4% of Esperion Therapeutics shares are owned by institutional investors. 32.7% of Lifecore Biomedical shares are owned by company insiders. Comparatively, 1.6% of Esperion Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Esperion Therapeutics beats Lifecore Biomedical on 10 of the 14 factors compared between the two stocks.

How does Lifecore Biomedical compare to Evommune?

Lifecore Biomedical (NASDAQ:LFCR) and Evommune (NYSE:EVMN) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings, profitability and media sentiment.

In the previous week, Evommune had 11 more articles in the media than Lifecore Biomedical. MarketBeat recorded 13 mentions for Evommune and 2 mentions for Lifecore Biomedical. Lifecore Biomedical's average media sentiment score of 1.89 beat Evommune's score of -0.53 indicating that Lifecore Biomedical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lifecore Biomedical	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Evommune	1 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Negative

Evommune has a net margin of 0.00% compared to Lifecore Biomedical's net margin of -25.43%. Evommune's return on equity of 0.00% beat Lifecore Biomedical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lifecore Biomedical	-25.43%	-1,643.15%	-14.40%
Evommune	N/A	N/A	N/A

83.4% of Lifecore Biomedical shares are held by institutional investors. 32.7% of Lifecore Biomedical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Lifecore Biomedical has higher revenue and earnings than Evommune. Lifecore Biomedical is trading at a lower price-to-earnings ratio than Evommune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lifecore Biomedical	$128.87M	1.53	-$35.26M	-$0.94	N/A
Evommune	$13M	36.79	-$68.87M	-$9.50	N/A

Lifecore Biomedical presently has a consensus target price of $6.50, indicating a potential upside of 23.81%. Evommune has a consensus target price of $45.63, indicating a potential upside of 243.59%. Given Evommune's stronger consensus rating and higher possible upside, analysts clearly believe Evommune is more favorable than Lifecore Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lifecore Biomedical	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Evommune	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	2.86

Summary

Evommune beats Lifecore Biomedical on 10 of the 16 factors compared between the two stocks.

How does Lifecore Biomedical compare to Vor Biopharma?

Lifecore Biomedical (NASDAQ:LFCR) and Vor Biopharma (NASDAQ:VOR) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, institutional ownership, media sentiment, profitability and earnings.

Vor Biopharma has a net margin of 0.00% compared to Lifecore Biomedical's net margin of -25.43%. Vor Biopharma's return on equity of 0.00% beat Lifecore Biomedical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lifecore Biomedical	-25.43%	-1,643.15%	-14.40%
Vor Biopharma	N/A	N/A	N/A

Lifecore Biomedical currently has a consensus price target of $6.50, indicating a potential upside of 23.81%. Vor Biopharma has a consensus price target of $42.25, indicating a potential upside of 129.49%. Given Vor Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Vor Biopharma is more favorable than Lifecore Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lifecore Biomedical	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Vor Biopharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82

In the previous week, Vor Biopharma had 1 more articles in the media than Lifecore Biomedical. MarketBeat recorded 3 mentions for Vor Biopharma and 2 mentions for Lifecore Biomedical. Lifecore Biomedical's average media sentiment score of 1.89 beat Vor Biopharma's score of 0.94 indicating that Lifecore Biomedical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lifecore Biomedical	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Vor Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

83.4% of Lifecore Biomedical shares are held by institutional investors. Comparatively, 97.3% of Vor Biopharma shares are held by institutional investors. 32.7% of Lifecore Biomedical shares are held by insiders. Comparatively, 0.3% of Vor Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Vor Biopharma has lower revenue, but higher earnings than Lifecore Biomedical.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lifecore Biomedical	$128.87M	1.53	-$35.26M	-$0.94	N/A
Vor Biopharma	N/A	N/A	N/A	N/A	N/A

Lifecore Biomedical has a beta of 1.06, suggesting that its share price is 6% more volatile than the broader market. Comparatively, Vor Biopharma has a beta of 1.71, suggesting that its share price is 71% more volatile than the broader market.

Summary

Vor Biopharma beats Lifecore Biomedical on 10 of the 13 factors compared between the two stocks.

Get Lifecore Biomedical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LFCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LFCR vs. The Competition

Export

Metric	Lifecore Biomedical	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$186.05M	$3.66B	$7.07B	$12.45B
Dividend Yield	N/A	2.20%	2.66%	6.16%
P/E Ratio	-5.59	20.90	27.25	24.87
Price / Sales	1.53	341.80	540.68	102.84
Price / Cash	N/A	143.77	48.53	58.59
Price / Book	12.50	8.75	11.01	6.54
Net Income	-$35.26M	$23.81M	$3.57B	$336.70M
7 Day Performance	-9.48%	3.60%	2.31%	2.88%
1 Month Performance	8.25%	3.72%	1.39%	0.64%
1 Year Performance	-34.05%	68.80%	36.71%	31.34%

Lifecore Biomedical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LFCR Lifecore Biomedical	1.6896 of 5 stars	$5.25 +5.8%	$6.50 +23.8%	-35.3%	$186.05M	$128.87M	N/A	690	News Coverage Positive News
ANNX Annexon	3.3943 of 5 stars	$5.28 +4.8%	$16.00 +203.0%	+137.9%	$825.77M	N/A	N/A	60	High Trading Volume
SLDB Solid Biosciences	2.5604 of 5 stars	$8.79 +5.9%	$17.00 +93.4%	+105.1%	$817.13M	N/A	N/A	100	News Coverage Positive News Gap Up
ESPR Esperion Therapeutics	2.7145 of 5 stars	$3.16 flat	$5.54 +75.3%	+221.0%	$814.31M	$403.14M	N/A	200	Positive News
EVMN Evommune	2.23 of 5 stars	$24.28 +7.7%	$49.25 +102.8%	N/A	$812.21M	$13M	N/A	45	News Coverage Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LFCR) was last updated on 7/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lifecore Biomedical (LFCR) Competitors

LFCR vs. ANNX, SLDB, ESPR, EVMN, and VOR

How does Lifecore Biomedical compare to Annexon?

Summary

How does Lifecore Biomedical compare to Solid Biosciences?

Summary

How does Lifecore Biomedical compare to Esperion Therapeutics?

Summary

How does Lifecore Biomedical compare to Evommune?

Summary

How does Lifecore Biomedical compare to Vor Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LFCR vs. The Competition

Lifecore Biomedical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lifecore Biomedical (LFCR) Competitors

LFCR vs. ANNX, SLDB, ESPR, EVMN, and VOR

How does Lifecore Biomedical compare to Annexon?

Which has stronger valuation and earnings, LFCR or ANNX?

Do insiders and institutionals believe in LFCR or ANNX?

Do analysts rate LFCR or ANNX?

Does the media refer more to LFCR or ANNX?

Is LFCR or ANNX more profitable?

Which has more risk and volatility, LFCR or ANNX?

Summary

How does Lifecore Biomedical compare to Solid Biosciences?

Which has better earnings and valuation, LFCR or SLDB?

Do analysts rate LFCR or SLDB?

Does the media refer more to LFCR or SLDB?

Do institutionals & insiders have more ownership in LFCR or SLDB?

Is LFCR or SLDB more profitable?

Which has more volatility and risk, LFCR or SLDB?

Summary

How does Lifecore Biomedical compare to Esperion Therapeutics?

Which has more risk and volatility, LFCR or ESPR?

Which has higher valuation and earnings, LFCR or ESPR?

Is LFCR or ESPR more profitable?

Do analysts prefer LFCR or ESPR?

Does the media favor LFCR or ESPR?

Do insiders & institutionals have more ownership in LFCR or ESPR?

Summary

How does Lifecore Biomedical compare to Evommune?

Does the media favor LFCR or EVMN?

Is LFCR or EVMN more profitable?

Do institutionals and insiders believe in LFCR or EVMN?

Which has higher valuation and earnings, LFCR or EVMN?

Do analysts prefer LFCR or EVMN?

Summary

How does Lifecore Biomedical compare to Vor Biopharma?

Is LFCR or VOR more profitable?

Do analysts recommend LFCR or VOR?

Does the media favor LFCR or VOR?

Do institutionals and insiders hold more shares of LFCR or VOR?

Which has higher valuation & earnings, LFCR or VOR?

Which has more risk & volatility, LFCR or VOR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LFCR vs. The Competition

Lifecore Biomedical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools